JIAO FENG: Open Payments
NPI 1326546912 · ROCKVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$951 in 21 payments from 7 companies in 2025. Trend: 2023 $431 · 2024 $355 · 2025 $951
Food & beverage: $891Education: $60
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 11 | $380 |
| Astellas Pharma US Inc | 3 | $202 |
| Madrigal Pharmaceuticals | 1 | $143 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $100 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $91 |
| Amgen Inc. | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $14 |
Products named: REZDIFFRA, Veozah, Livdelzi, Vemlidy, NEFFY, Kerendia, EVENITY, SHINGRIX.
Industry payments across MD — which companies pay providers there.
